Women’s Health Meets Drug Design and Medical Research

We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers.

For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review.

Journalist: Jessica Davis Plüss
Host: Jo Fahy
Audio editor/video journalist: Michele Andina
Distribution and Marketing: Xin Zhang

SWI swissinfo.ch is a public service media company based in Bern, Switzerland.

Chapters

• 0:00 Setting The Stage: Science Series
• 0:58 The Gender Gap In Drug Development
• 2:04 Lakembi’s Results Split By Sex
• 3:52 Why Differences May Exist
• 4:56 Regulators Weigh Benefits And Risks
• 5:47 Funding Shifts And Swiss Initiatives
• 7:19 From Male Mice To Human Bias
• 8:56 Clinical Trials And Who Gets Included
• 11:17 When Care Differs: Cardiac Case Study
• 13:13 Policy Progress In US And Europe
• 14:38 Switzerland’s Catch-Up And Reforms
• 15:53 Political Pushback And Corporate Responses
• 17:06 Changing Minds Inside Science
• 17:32 Wrap-Up And What’s Next